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Introduction
Proteins misfolded in the ER are degraded by the proteasome via 
a series of events collectively termed ER-associated degradation 
(Xie and Ng, 2010; Smith et al., 2011; Brodsky, 2012). Among 
the various pathways used, the best characterized, particularly 
in yeast, is ER-associated glycoprotein degradation (gpERAD) 
in which two-step mannose trimming from high-mannose-type 
oligosaccharides plays crucial roles (Molinari, 2007; Hosokawa 
et al., 2010a; Kamiya et al., 2012). 1,2-mannosidase Mns1 
catalyzes the first step, conversion of Man9GlcNAc2 (M9) to 
Man8GlcNAc2 isomer B (M8B), and 1,2-mannosidase Htm1 
catalyzes the second step, conversion of M8B to oligosaccha-
rides with the 1,6-mannose exposed (M1,6E; Fig. 1, C and E; 
and see Fig. 5 A). These products are then recognized by lectin 
Yos9 for subsequent disposal (Quan et al., 2008).
The mammalian ER expresses ER mannosidase I (ERmanI) 
as the sole homologue of Mns1, but expresses multiple ho-
mologues of Htm1, namely, EDEM1, EDEM2, and EDEM3 
(Fig. 1, A and B). The exact roles of all these proteins in mam-
malian gpERAD have remained elusive. Overexpression and 
biochemical experiments indicated that ERmanI converted M9 
to M8B (Gonzalez et al., 1999; Hosokawa et al., 2003). Over-
expression of EDEM1 or EDEM3 but not EDEM2 promoted 
mannose trimming at various steps, including the second step 
(Hosokawa et al., 2003, 2010b; Mast et al., 2005; Hirao et al., 
2006; Olivari et al., 2006). These results pointed to ERmanI as 
the first-step enzyme and to EDEM1 and EDEM3 as the second- 
step enzymes, and suggested that EDEM2 lacks -mannosidase 
activity. However, this was puzzling to us because it had origi-
nally been proposed that EDEM1 has no 1,2-mannosidase 
activity (Hosokawa et al., 2001) and because it was also suggested 
that ERmanI is involved in the formation of Man7-5GlcNAc2  
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Figure 1. Characterization of DT40 and HCT116 cell lines in regard to gpERAD. (A) Schematic structures of yeast Mns1 and Htm1 and their homologues 
in chickens (g) and humans (h). Sequence identities are shown as percentages. (B) Phylogenic tree calculated by the neighbor-joining method. (C) Sche-
matic structure of Glc3Man9GlcNAc2. (D) Elution profiles of N-glycans prepared from total cellular glycoproteins of WT DT40 and HCT116 cells. This 
experiment was completed once. (E) Isomer composition of N-glycans obtained from D. nd, not detected. (F) Endogenous mRNA levels encoding chicken 
and human EDEM1, EDEM2, EDEM3, SEL1L, and ERmanI relative to chicken and human GAPDH mRNA level, respectively, expressed in WT DT40 or 
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with M1,6E, based on the results of overexpression (Hosokawa 
et al., 2003), knockdown (Avezov et al., 2008), and biochem-
istry (Aikawa et al., 2012). Moreover, the finding that EDEM1 
recognized not only misfolded glycoproteins but also misfolded 
nonglycoproteins and delivered them to the ER membrane for 
destruction by binding to the carbohydrate moiety of its down-
stream component SEL1L (Cormier et al., 2009) generated 
controversy as to whether EDEMs function as 1,2-mannosi-
dases for mannose trimming or as lectins for substrate delivery 
(Tamura et al., 2010). We have therefore conducted gene knock-
out (KO) analyses in chicken and human cell lines to resolve 
this controversy and to determine which proteins catalyze the 
two key steps of mannose trimming in mammalian gpERAD.
Results and discussion
We started by determining the N-glycan profiles of total cel-
lular glycoproteins prepared from wild-type (WT) DT40 cells 
derived from chicken B lymphocytes and HCT116 cells derived 
from human colonic carcinoma, both of which express Mns1 and 
Htm1 homologue mRNAs at comparable levels (Fig. 1 F). We 
focused on high-mannose-type oligosaccharides with the elu-
tion positions shown in Fig. 1 D. For comparison, Fig. 1 E shows 
the amount of each high-mannose-type oligosaccharide relative 
to the total amount of high-mannose-type oligosaccharides. M9 
and M8B levels in the two cell types were comparable, con-
sistent with the results obtained with HepG2 cells (Hosokawa 
et al., 2010b). In connection with this, our literature search un-
raveled an interesting difference between yeast and mammalian 
gpERAD. Namely, total N-glycans obtained after 10–20-min 
pulse labeling of yeast cells consisted almost exclusively of M8 
(Clerc et al., 2009), indicating that conversion of M9 to M8B 
by Mns1 is highly efficient and occurs regardless of protein 
folding/misfolding status. Therefore, conversion of M8B to 
M1,6E by Htm1 is the initiating and rate-limiting step in yeast 
gpERAD (Gauss et al., 2011). In contrast, total N-glycans ob-
tained after 30-min pulse labeling of HEK293 cells consisted 
predominantly of M9 (Hirao et al., 2006), indicating that con-
version of M9 to M8B is inefficient in human cells.
We knocked out MnsI and Htm1 homologues separately 
in DT40 cells using homologous recombination, which is ex-
ceptionally efficient in this cell line (Fig. S1). RT-PCR showed 
no expression of gEDEM1, gEDEM3, or gERmanI mRNA 
in the respective KO cells (Fig. 2 A). Although gEDEM2-KO 
cells expressed some short gEDEM2 mRNAs, these mRNAs 
had internal deletions and therefore failed to produce any pro-
teins when translated in vitro (Fig. S1 K). All of these KO cells 
grew nearly as fast as WT cells (Fig. 2 B). We determined their 
N-glycan profiles in the same way as for WT cells (Fig. S2, 
A and B) and identified the oligosaccharides whose contents 
in KO cells exceeded those in untreated WT cells. The results 
are shown as the increase over WT (percentage of untreated 
WT cells subtracted from percentage of each type of KO cell) 
in Fig. 2 C. When WT cells were treated with kifunensine, an 
inhibitor of ERmanI (Tremblay and Herscovics, 1999), M9 be-
came predominant, as expected, but surprisingly M9 increased 
only slightly in gERmanI-KO cells (Fig. 2 C). This finding 
Figure 2. Effect of gene disruption on chicken gpERAD. (A) RT-PCR to am-
plify cDNA corresponding to the four 1,2-mannosidase mRNA expressed 
in DT40 cells of various genotypes. (B) Doubling time of WT and four 
1,2-mannosidase KO cells (n = 3). (C) Display of oligosaccharides whose 
contents in kifunensine (Kif; 10 µg/ml, 6 h)-treated WT DT40 cells and four 
1,2-mannosidase KO cells exceeded those in kifunensine-untreated WT 
cells with an increase over WT (%), as determined from isomer composi-
tion of their N-glycans (Fig. S2, A and B), which was completed once. 
Asterisks denote oligosaccharides whose contents did not exceed those in 
kifunensine-untreated WT cells. (D) Immunoblotting of cell lysates prepared 
from kifunensine-untreated or -treated WT DT40 cells and from the four 
1,2-mannosidase KO cells using anti-chicken ATF6 (gATF6) antibody. 
(E) Cycloheximide chase to determine the degradation rate of endogenous 
gATF6 in kifunensine-untreated or -treated WT DT40 cells and in the four 
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profiles (Fig. S3, F and G) revealed that conversion of M9 to 
M8B was blocked in hEDEM2-KO cells as effectively as in 
kifunensine-treated WT HCT116 cells and that the level of M8B 
increased in hEDEM1-KO and hEDEM3-KO cells (Fig. 3 F). 
Thus, all endogenous hEDEMs function as 1,2-mannosidases. 
Endogenous human ATF6 migrated more slowly in kifunen-
sine-treated WT and hEDEM2-KO cells than in untreated WT 
cells (Fig. 3 G), and this difference was lost after treatment with 
endoglycosidase H, as expected (Fig. 3 H). This difference in 
migration was also observed in different KO strains (Fig. S3 H). 
ATF6 in hEDEM3-KO cells appeared to migrate with a speed 
between that in untreated WT and hEDEM2-KO cells (Fig. 3 G), 
reflecting the marked increase in M8B level (Fig. 3 F). Degrada-
tion of endogenous ATF6 was blocked in WT HCT116 cells 
treated with MG132 or kifunensine, as expected, and was most 
effectively blocked in hEDEM2-KO cells (Fig. 4 A).
The enzymatic activity of Mns1 is strongly dependent on 
the EF hand motif in the mannosidase homology domain, and 
mutation of the glutamic acid within it (Fig. 4 B, red circle) 
is known to cause inactivation (Lipari and Herscovics, 1999). 
Importantly, when myc-tagged hATF6 (full length; Fig. 4 C, 
top) or hATF6(C)-BACE(TM)-TAP (Horimoto et al., 2013; a 
shorter, artificial yet functional transmembrane protein contain-
ing the luminal region of hATF6 and the transmembrane region 
of BACE501, which is subjected to gpERAD; Fig. 4 C, bottom) 
was cotransfected with Flag-tagged hEDEM2 in hEDEM2-KO 
cells, these proteins migrated in SDS-PAGE at the same positions 
as in WT cells (Fig. 4 D). In contrast, no such rescue effect was 
observed with Flag-tagged mutant hEDEM2-E117Q (Fig. 4 D). 
These differences in migration were also observed for endog-
enous hATF6 in WT cells and hEDEM2-KO cells stably ex-
pressing Flag-tagged hEDEM2 or hEDEM2-E117Q (Fig. 4 E). 
Most importantly, stable introduction of Flag-tagged hEDEM2, 
but not Flag-tagged hEDEM2-E117Q, into hEDEM2-KO cells 
restored degradation of endogenous hATF6 (Fig. 4 F).
The mechanism of mammalian gpERAD was originally pro-
posed based on the results of yeast genetics and biochemistry and 
overexpression in mammalian cells. However, here our pioneering 
application of TALEN to dissect and identify the functions of mul-
tigene family members (EDEMs) in human cells revealed that the 
roles of Mns1 and Htm1 homologues in mammalian gpERAD are 
completely discordant with those in that earlier proposed mecha-
nism. The Mns1 homologue ERmanI plays a minor role in the con-
version of M9 to M8B, the first step of gpERAD, unlike in yeast, 
whereas the previously passed-over Htm1 homologue EDEM2 
most surprisingly plays a major role (Fig. 5 B).
We found that although hEDEM1 appeared to possess the 
weakest 1,2-mannosidase activity among the three hEDEMs 
(Fig. 3 F), deletion of hEDEM1 significantly delayed the degrada-
tion of hATF6 (Fig. 4 A). These observations are consistent with 
previous studies on EDEM1 (Hosokawa et al., 2010b; Ron et al., 
2011; Shenkman et al., 2013). We also found that overexpression 
of both WT hEDEM1 and enzymatically inactive mutant 
hEDEM1-E225Q enhanced degradation of hATF6(C)-BACE 
(TM)-TAP (Fig. S3 I). This suggests that hEDEM1 can function 
in gpERAD independently of its 1,2-mannosidase activity, when 
overexpressed or up-regulated by the unfolded protein response 
indicates that the Mns1 homologue plays only a minor role in 
the conversion of M9 to M8B in DT40 cells, but is consistent 
with the finding that purified recombinant human ERmanI ex-
hibited much weaker 1,2-mannosidase activity toward M9 at-
tached to a native protein than to M9 attached to pyridylamine 
(Aikawa et al., 2012) and may be correlated with the unexpected 
localization of endogenous ERmanI at the Golgi apparatus (Pan 
et al., 2011). The fact that the levels of M8A, M7B, and M6 also 
increased in gERmanI-KO cells (Fig. 2 C) indicates that gERmanI 
appears to trim the outermost mannose of the B branch ran-
domly rather than to convert M9 to M8B specifically.
Contrary to our strong expectations from previous results 
(Mast et al., 2005), we were surprised to find that conversion of 
M9 to M8B was blocked as effectively in gEDEM2-KO cells as 
in WT cells treated with kifunensine (Fig. 2 C), indicating that 
the first-step mannose trimming in DT40 cells is mainly caused 
by gEDEM2 and that kifunensine inhibits both gERmanI and 
gEDEM2. In contrast, the level of M8B increased in gEDEM1-
KO and gEDEM3-KO cells (Fig. 2 C), indicating that EDEM1 
and EDEM3 are the second-step enzymes. These differences in 
N-glycan profiles were well reflected by the mobility in SDS-
PAGE of ATF6, a type II transmembrane glycoprotein in the 
ER that functions as an unfolded protein response transducer 
(Haze et al., 1999): endogenous ATF6 migrated more slowly in 
kifunensine-treated WT and gEDEM2-KO cells than in other 
cell types (Fig. 2 D). We recently showed that ATF6 undergoes 
gpERAD in DT40 cells (Horimoto et al., 2013). Because its 
degradation by the proteasome is completely blocked by kifu-
nensine treatment, it is a highly suitable substrate to determine 
the effect on gpERAD. Cycloheximide chase clearly showed 
that degradation of endogenous ATF6 occurred normally in 
gERmanI-KO cells, whereas it was most effectively blocked in 
kifunensine-treated WT and gEDEM2-KO cells (Fig. 2 E), as 
expected from the N-glycan profiles.
We then knocked out three EDEMs in the human HCT116 
diploid cell line (Ochiai et al., 2014) using the transcription 
activator-like effector nuclease (TALEN) method (Joung and 
Sander, 2013). Specifically, we used the recently developed 
Platinum TALEN technology, which appears to have higher 
activity than previously reported methods (Sakuma et al., 
2013). Single introduction of Platinum TALEN designed to 
cleave within exon 1 encoding the signal sequence of hEDEM1, 
hEDEM2, or hEDEM3, together with the respective target-
ing vector containing positive and negative selection markers, 
produced homo-KOs with efficiency of 20%, 19%, or 45%, re-
spectively, and the ampicillin-resistance gene for Escherichia 
coli selection and the diphtheria toxin-A fragment gene were 
not incorporated into the genome when correctly targeted 
(Fig. 3, A and B). Genomic PCR (Fig. 3 C) and Southern blot 
hybridization (Fig. S3, A–D) showed incorporation of the drug- 
resistance gene at the expected locus in each case (four probes we 
tested did not work for hEDEM1 Southern blot hybridization), 
and RT-PCR revealed no expression of hEDEM1, hEDEM2, or 
hEDEM3 mRNA in the respective KO cells (Fig. 3 D). These 
KO cells grew as fast as WT cells (Fig. 3 E). Immunoblotting 
showed that ER stress marker proteins BiP, ATF4, and XBP1(S) 
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consistent with our placement of EDEM1 and EDEM3 down-
stream of EDEM2 (Fig. 5 B).
Nonetheless, conversion of M9 to M8B by hEDEM2 is 
much slower than that by yeast Mns1 because M9 and M8B 
exist at comparable levels in human cells (Fig. 1 E). In other 
words, mammalian gpERAD has two rate-limiting steps in man-
nose trimming. As overexpression of hEDEM2 or hEDEM3 did 
not affect the level of hATF6(C)-BACE(TM)-TAP (Fig. S3 I), 
the expression levels of EDEM2 or EDEM3 are not the primary 
determinants of the speed of mannose trimming. Interestingly, 
it was recently shown that EDEM1 and EDEM2 bind to ricin 
A chain, which is retrotranslocated from the ER to the cytosol 
similarly to ERAD substrates, but they bind much less efficiently 
to its P250A mutant, which is less hydrophobic than the WT 
(Sokołowska et al., 2011; Słomińska-Wojewódzka et al., 2014), 
during ER stress (Yoshida et al., 2003), likely as a lectin for sub-
strate delivery as proposed previously (Cormier et al., 2009).
The results obtained with TALEN-based KO in human 
cells are consistent with those we obtained here with conven-
tional KO in chicken cells, demonstrating the reliability of 
TALEN technology. Particularly in human cells, the summation 
of the increase of M8B levels in hEDEM1-KO and hEDEM3-
KO cells was nearly identical to the increase in M9 level in 
hEDEM2-KO cells (Fig. 3 F), indicating that conversion of 
M8B to M1,6E, the second step, is performed mainly by 
hEDEM3 and to a lesser extent by hEDEM1, not by hEDEM2. 
In connection with this subject, it was recently shown that 
SEL1L, a partner protein of the E3 ligase HRD1 spanning the 
ER membrane, binds to EDEM1 and EDEM3 but not to EDEM2 
(Saeed et al., 2011; confirmation in Fig. S3 J). These results are 
Figure 3. Effect of gene disruption on human 
gpERAD. (A) Strategy for TALEN-mediated gene 
disruption. Cleavage of the exon 1 encoding 
the signal sequence of human EDEM1, EDEM2, 
or EDEM3 with the designed TALEN facilitates 
subsequent homologous recombination with the 
respective targeting vector containing both posi-
tive and negative selection markers. (B) Results 
of screening. The presence (amp +) or absence 
(amp ) of the ampicillin-resistance gene in 
targeted alleles was checked by genomic PCR. 
(C) Genomic PCR to confirm homologous recom-
bination in HCT116 cells of various genotypes. 
Asterisks denote nonspecific bands. (D) RT-PCR 
to amplify cDNA corresponding to hEDEM1, 
hEDEM2, or hEDEM3 mRNA expressed in 
HCT116 cells of various genotypes. The full-
length cDNA and cDNA lacking the exon 6 were 
amplified as hEDEM1. (E) Doubling time of WT 
and three hEDEM-KO cells (n = 4). (F) Display, 
similarly to Fig. 2 C, of oligosaccharides whose 
contents in kifunensine (Kif; 10 µg/ml, 12 h)-
treated WT HCT116 and three hEDEM-KO cells 
exceeded those in kifunensine-untreated WT cells 
with an increase over WT (%), as determined from 
isomer composition of their N-glycans (Fig. S3, 
F and G), which was completed once. Asterisks 
denote oligosaccharides whose contents did not 
exceed those in kifunensine-untreated WT cells. 
(G) Immunoblotting of cell lysates prepared from 
kifunensine-untreated or -treated WT HCT116 
cells and from three hEDEM-KO cells using anti-
human ATF6 (hATF6) antibody. (H) Immuno-
blotting of cell lysates prepared from WT and 
hEDEM2-KO HCT116 cells with or without endo-
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recognition by lectin OS-9 (Fig. 5 B). This is more sophisticated 
than single check by Htm1 in yeast cells, as it avoids the unnec-
essary destruction of proteins, whose synthesis is energy expen-
sive, and allows the escape of folded proteins from ERAD.
Materials and methods
Construction of plasmids
Recombinant DNA techniques were performed according to standard 
procedures (Sambrook et al., 1989) and the integrity of all constructed 
suggesting that they recognize not only sugar structures but also 
protein structures.
Taking the aforementioned findings all together we pro-
pose that mammalian cells double check gpERAD substrates by 
evolving a novel-type Htm1 homologue that catalyzes the first 
mannose trimming step from M9 and thereby expressing three 
EDEMs with different specificity for glycoprotein folding/ 
misfolding, first by EDEM2 (for conversion of M9 to M8B) and 
then by EDEM1/3 (for conversion of M8B to M1,6E), before 
Figure 4. Requirement for 1,2-mannosidase activity of hEDEM2 in human gpERAD. (A) Pulse chase to determine the degradation rate of endogenous 
hATF6 in WT HCT116 cells with or without kifunensine or MG132 treatment and in three hEDEM-KO cells (n = 3). (B) Alignment of amino acid sequences 
around the EF hand motif, which is essential for the 1,2-mannosidase activity of Mns1, with those of Htm1 and their homologues in chicken and human. 
Identical amino acids are highlighted. (C) Schematic structure of hATF6 and hATF6(C)-BACE(TM)-TAP. Potential N-glycosylation sites are shown sche-
matically. (D) Immunoblotting of cell lysates prepared from WT and hEDEM2-KO HCT116 cells in which Myc-hATF6 (top) or hATF6(C)-BACE(TM)-TAP 
(bottom) was expressed by transfection together with hEDEM2-Flag or hEDEM2-E117Q-Flag, using anti–c-myc and anti-Flag antibodies. (E) Immunoblottig 
of cell lysates prepared from WT HCT116, hEDEM2-KO, and hEDEM2-KO cells stably expressing hEDEM2-Flag or hEDEM2-E117Q-Flag using anti-human 
ATF6 and anti-Flag antibodies. (F) Pulse chase to determine the degradation rate of endogenous hATF6 in HCT116 hEDEM2-KO and hEDEM2-KO cells 
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from Sigma-Aldrich; MG132 from Peptide Institute; and Z-VAD-fmk 
from Promega.
Immunological techniques
Immunoblotting analysis was performed according to the standard proce-
dure (Sambrook et al., 1989) as described previously (Ninagawa et al., 
2011). Chemiluminescence obtained using Western blotting Luminol Re-
agent (Santa Cruz Biotechnology, Inc.) was detected using an LAS-3000mini 
LuminoImage analyzer (Fujifilm). Rabbit anti–chicken ATF6 (Horimoto 
et al., 2013) and rabbit anti–human ATF6 (Haze et al., 1999) antibodies 
were raised previously. Mouse anti–c-myc antibody (9E10) was obtained 
from Wako Pure Chemical Industries; mouse anti-Flag antibody from 
Sigma-Aldrich; mouse anti-KDEL antibody from Medical and Biological 
Laboratories; rabbit anti–human ATF4 and rabbit anti–mouse XBP1 anti-
bodies from Santa Cruz Biotechnology, Inc.; and rabbit anti–human 
GAPDH from Trevigen. Rabbit anti–human SEL1L antibody was a gift from 
N. Hosokawa (Kyoto University, Kyoto, Japan).
Pulse-chase experiments and subsequent immunoprecipitation were 
performed according to procedures described previously (Ninagawa 
et al., 2011). After incubation for 30 min in methionine- and cysteine-free 
Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 2 mM 
glutamine and 10% dialyzed fetal bovine serum, cells were pulse labeled 
with 2.0 Mbq/dish EXPRE35S35S protein labeling mixture (PerkinElmer) and 
then chased in fresh complete medium. Cells were lysed in buffer A (50 mM 
Tris/Cl, pH 8.0, containing 1% NP-40, 150 mM NaCl, protease inhibitor 
cocktail (Nacalai), 20 µM MG132, and 2 µM Z-VAD-fmk). Immunoprecipi-
tation was performed using anti-hATF6 antibody and protein A–coupled 
Sepharose beads (GE Healthcare). Beads were washed with high salt buf-
fer (50 mM Tris/Cl, pH 8.0, containing 1% NP-40 and 150 mM NaCl) 
twice, washed with PBS, and heated at 65°C in Laemmli’s sample buffer. 
Immunoprecipitates were subjected to SDS-PAGE, and radioactive bands 
were analyzed using a FLA-3000G FluoroImage analyzer (Fujifilm).
Quantitative RT-PCR
Quantitative RT-PCR was performed using the SYBR Green method (Ap-
plied Biosystems) using a pair of primers, namely, 5-CTGCACATGGCT-
CATGACCTA-3 and 5-ACCCGAGGATACGGAATTCC-3 for gEDEM1, 
5-CTGAAGGCACTGTGGAAAAACC-3 and 5-GCCACCCATTTGGC-
AGTTAC-3 for gEDEM2, 5-GCGCAGCAGCAATTTGGT-3 and 5-CC-
GCTCCAACTCCACTATCTTT-3 for gEDEM3, 5-TTTGGTGTGCAACAA-
CCTATG-3 and 5-CCTCTTATTGGACTGCTCTTCA-3 for gSEL1L, 5-AGT-
GCCAAGATGGATCACTTG-3 and 5-TGATCAGCAGTCAATCCATTG-3 for 
gERmanI, 5-CTGATGCCCCCATGTTTGTG-3 and 5-GCACGATGCATTGCTG-
ACA-3 for gGAPDH, 5-AGTTCCTCCTGACACCAATA-3 and 5-GTCGACT-
CAGAATCCCAAAT-3 for hEDEM1, 5-CGCTTCGATGACTGGTACCT-3 
and 5-TAGGCCTCCAAGGACTGGAA-3 for hEDEM2, 5-ATTAGCCAGC-
CACCTCTTCT-3 and 5-AGCAAAGCATCCATCCAAGT-3 for hEDEM3, 
5-GGTTTGGCACCGATGTAGAT-3 and 5-AGCTTGTGCACTGTGTTGCT-3 
plasmids was confirmed by extensive sequencing analyses. Site-directed 
mutagenesis was performed using DpnI. p3*flag-CMVTM-14 expression 
vector (Sigma-Aldrich) was used to express a protein tagged with Flag at 
the C terminus. Platinum TALEN plasmids were constructed as described 
previously (Sakuma et al., 2013). In brief, each DNA-binding module 
was assembled into ptCMV-136/63-VR vectors using the two-step Golden 
Gate cloning method. Assembled sequences were 5-TGGCGAGCGCTC-
GTCCTGgggctggtgctcctcCGGCTTGGCCTCCATGGA-3 for hEDEM1, 
5-TCCGGCTGCTCATCCCGctcggcctcctgtgcGCGCTGCTGCCTCAGCA-3 
for hEDEM2, and 5-TGTGGGTCCCCGGTTCCccagcgagcgcgatgGAGAC-
TAGTGGCGGCGA-3 for hEDEM3, where uppercase and lowercase letters 
indicate TALEN target sequences and spacer sequences, respectively.
Cell culture and transfection
DT40 cells were cultured and transfected as described previously (Ninagawa 
et al., 2011). HCT116 cells (CCL-247; ATCC) were cultured in Dulbecco’s 
modified Eagle’s medium (4.5 g/l glucose) supplemented with 10% 
fetal bovine serum, 2 mM glutamine, and antibiotics (100 U/ml penicillin 
and 100 µg/ml streptomycin) at 37°C in a humidified 5% CO2/95% 
air atmosphere. Transfection was performed using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. HCT116 cells stably 
expressing hEDEM2-Flag or hEDEM2-E117Q-Flag from p3*Flag-CMVTM14 
expression vector were selected after culture for 20 d in the presence of 
0.6 mg/ml G418.
Analysis of N-glycans of total cellular glycoproteins
Pyridylamination and structural identification of N-glycans of total cellular 
glycoproteins were performed as described previously (Hosokawa et al., 
2010b). In brief, N-glycans released from delipidated cells by hydrazinoly-
sis were reN-acetylated using acetic anhydrides, and then labeled with fluor-
escent 2-aminopyridine (Wako Pure Chemical Industries). Pyridylaminated 
(PA) oligosaccharides were fractionated by HPLC first on a TSK gel Amide-80 
(amide-silica) column (Tosoh) and second on a Shim-pack HRC-octadecyl 
silica column (Shimadzu). Elution times of individual peaks from the amide-
silica and octadecyl silica columns were normalized with respect to the de-
gree of polymerization of PA-isomalto-oligosaccharide and are represented 
in units of glucose. N-Glycan structures were identified based on their elu-
tion times from these columns in comparison with those of PA-glycans in the 
GALAXY database (Takahashi and Kato, 2003) and confirmed by cochro-
matography with standard PA-high mannose type oligosaccharides (Tomiya 
et al., 1991; Kamiya et al., 2008).
Reagents
Puromycin (0.5 µg/ml), histidinol (1 mg/ml), mycophenolic acid (15 µg/ml), 
blasticidin S (25 µg/ml), G418 (2 mg/ml for DT40 and 0.6 mg/ml for 
HCT116), and zeocin (1 mg/ml) were used for the selection and mainte-
nance of drug-resistant clones. Kifunensine was purchased from Cayman 
Chemical Company; endoglycosidase H from EMD Millipore; cycloheximide 
Figure 5. Models of yeast and mammalian 
gpERAD. (A) In yeast, high-mannose-type oli-
gosaccharide attached to asparagine (Glc3-
Man9GlcNAc2, G3M9) is first trimmed to 
M9 by glucosidases Gls1 and Gls2. M9 is 
trimmed to M8B by Mns1 and M8B is trimmed 
to M7A by Htm1. G1M9 is recognized by 
lectin chaperone Cne1 for folding, whereas 
M7A exposing 1,6-mannose is recognized 
by lectin Yos9 for subsequent degradation. 
The rate-limiting step in yeast gpERAD is the 
trimming from M8B to M7A. Refer to reviews 
by Molinari (2007) and Hosokawa et al. 
(2010a). (B) In mammals, G3M9 is trimmed 
to M9 by glucosidase I (GI) and glucosidase II 
(GII), homologues of yeast Gls1 and Gls2, 
respectively. G1M9 is recognized by lectin 
chaperones calnexin (CNX) and calreticulin 
(CRT), homologues of yeast Cne1, for folding. 
As our current results unambiguously show that 
M9 is mainly trimmed to M8B by EDEM2 and 
that M8B is trimmed by EDEM1 and EDEM3 
to Man7-5GlcNAc2, which are recognized by 
lectin OS-9, a homologue of yeast Yos9, for 
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(histidinol dehydrogenase [HisD]) gene was subcloned into the BamHI site 
of the pBluescript-5-3 arms (gEDEM1) to create pKO-gEDEM1-puromycin 
or pKO-gEDEM1-histidinol, respectively (Fig. S1 A). These constructs were 
transfected into DT40 cells by electroporation after linearization using SacI.
Construction of gEDEM2 targeting vector
The 3.2-kb fragment of the gEDEM2 gene used for the 5 arm was amplified 
by PCR from DT40 cell genomic DNA using the primers 5-GGACTAGT-
TAGCAGCAGGAGACCCTTGT-3 and 5-CGGGATCCGCTCGTAGGC-
GTGGTAGAAC-3, and then subcloned between the SpeI and BamHI sites 
of pBluescript II KS (+) vector to create the pBluescript-5 arm (gEDEM2). 
The 2.4-kb fragment of the gEDEM2 gene used for the 3 arm was ampli-
fied similarly using the primers 5-CGGGATCCGCAATGTCACCGAGTTC-
CAG-3 and 5-CCCTCGAGACCAATCCCAGCAGTACAGG-3, and then 
subcloned between the BamHI and XhoI sites of the pBluescript-5 arm 
(gEDEM2) to create the pBluescript-5-3 arms (gEDEM2). The neomycin-
resistance gene flanked by loxP sites designated Neo-loxP or blasticidin 
S-resistance gene flanked by loxP sites designated Bsr-loxP was subcloned into 
the BamHI site of the pBluescript-5-3 arms (gEDEM2) to create pKO-gEDEM2-
neomycin or pKO-gEDEM2-blasticidin S, respectively. HisD was also sub-
cloned into the BamHI site of the pBluescript-5-3 arms (gEDEM2) to create 
pKO-gEDEM2-histidinol (Fig. S1 D). These constructs were transfected into 
DT40 cells by electroporation after linearization using SpeI or ScaI.
Construction of gEDEM3 targeting vector
The 2.2-kb fragment of the gEDEM3 gene used for the 5 arm was amplified 
by PCR from DT40 cell genomic DNA using the primers 5-CGAGCTCCCAT-
GAGCAAGGAGGAGAAG-3 and 5-CGGGATCCTGGTCAAACATTTC-
CAGCAC-3, and then subcloned between the SacI and BamHI sites of 
pBluescript II KS (+) vector to create the pBluescript-5 arm (gEDEM3). The 
3.4-kb fragment of the gEDEM3 gene used for the 3 arm was amplified 
similarly using the primers 5-CGGGATCCTTCTCCCTGACCTTGATTGA-3 
and 5-CCCTCGAGAATCGGCTTAAAGCTGCAAA-3, and then subcloned 
between the BamHI and XhoI sites of the pBluescript-5 arm (gEDEM3) to 
create the pBluescript-5-3 arms (gEDEM3). The Neo-loxP was subcloned 
into the BamHI site of the pBluescript-5-3 arms (gEDEM3) to create pKO-
gEDEM3-neomycin. The HisD or mycophenolic acid–resistance gene, des-
ignated E. coli xanthine-guanine phosphoribosyltransferase (EcoGPT), was 
also subcloned into the BamHI site of the pBluescript-5-3 arms (gEDEM3) 
to create pKO-gEDEM3-histidinol or pKO-gEDEM3-mycophenolic acid, re-
spectively (Fig. S1 G). These constructs were transfected into DT40 cells by 
electroporation after linearization using PvuI or SacI.
Construction of gERmanI targeting vector
The 3.6-kb fragment of the gERmanI gene used for the 5 arm was amplified 
by PCR from DT40 cell genomic DNA using the primers 5-ATAAGAATGC-
GGCCGCACATGAACACTGAACTGCTG-3 and 5-CGGGATCCGCTTC-
CATTTCTTCCAGAGAG-3, and then subcloned between the NotI and BamHI 
sites of pBluescript II KS (+) vector to create the pBluescript-5 arm (gERmanI). 
The 2.8-kb fragment of the gERmanI gene used for the 3 arm was amplified 
similarly using the primers 5-CCATCGATGACTACCCAGAGCTTTCACC-3 
and 5-CCGCTCGAGCAACTCAATCAAAATTCTG-3, and then subcloned 
between the ClaI and XhoI sites of the pBluescript-5 arm (gERmanI) to cre-
ate the pBluescript-5-3 arms (gERmanI). Neo-loxP or Puro-loxP was sub-
cloned into the BamHI site of the pBluescript-5-3 arms (gERmanI) to create 
pKO-gERmanI-neomycin or pKO-gERmanI-puromycin, respectively (Fig. S1 L). 
These constructs were transfected into DT40 cells by electroporation after 
linearization using NotI.
Construction of gEDEM1-, gEDEM2-, gEDEM3-, and gERmanI-KO cells
Exons encoding the N-terminal region of the mannosidase homology do-
main of gEDEM1, gEDEM2, or gEDEM3 were replaced with one of the five 
drug-resistance genes (Fig. S1, A, D, and G). Homologous recombination 
was checked by Southern blotting (Fig. S1, B, E, and H). We obtained two 
independent clones (/ #1 and #2), in which the allelic gEDEM1 genes 
were disrupted by HisD and Puro-loxP (Fig. S1, B and C). As RT-PCR analy-
sis showed that gEDEM1 mRNA was not expressed in these clones (Fig. S1 J), 
we used / #1 as gEDEM1-KO (Fig. 2 A). The gEDEM2 gene is en-
coded in chromosome 2, which is in trisomy in DT40 cells. We thereby ob-
tained two independent clones (// #1 and #2) in which all three 
alleles of the gEDEM2 gene were disrupted by Neo-loxP, HisD, and Bsr-
loxP (Fig. S1, E and F). Neo-loxP and Bsr-loxP were then eliminated from 
their genome using the Cre-loxP system to obtain // (loxP) #1 and 
#2 for further disruption (Fig. S1, E and F). RT-PCR analysis showed that 
these loxP clones expressed some shorter gEDEM2 mRNAs (Fig. S1 J). 
Thus, gEDEM2 cDNA was amplified by RT-PCR from WT cells and gEDEM2 
for hSEL1L, 5-CCCGAGCCTAGGGACAAGAT-3 and 5-CCCGAGCCTA-
GGGACAAGAT-3 for hERmanI, or 5-GACCCCTTCATTGACCTCAA-3 
and 5-TTGACGGTGCCATGGAATT-3 for hGAPDH. 2,000, 8,000, 20,000, 
80,000, and 200,000 molecules of plasmid carrying the respective gene 
were used as standards.
Southern blot hybridization
Southern blot hybridization was performed according to standard proce-
dures (Sambrook et al., 1989) as described previously (Ninagawa et al., 
2011). Specific probes were amplified by PCR from DT40 cell genomic 
DNA using the primers 5-TGAAACTTGCACTGCAGGAG-3 and 5-ACC-
CCCTTCGTAAGTGGTTC-3 for gEDEM1, 5-GAAGGCTCTGAAGGC-
ACTGT-3 and 5-TGTCGGATCCCTTTCAACTC-3 for gEDEM2, 5-AG-
CCGATTCACAGGAACATC-3 and 5-AAGAAGGGCAGTGCACAAAT-3 
for gEDEM3, or 5-AAATTATTCTGATGCACATG-3 and 5-CTCTTGTATG-
CATCGATATGf-3 for gERmanI, or from HCT116 cell genomic DNA using 
the primers 5-CCACTGACCCTAACAATTGC-3 and 5-AAATGAGGCA-
AAGTAATGCC-3 for hEDEM2 and 5-GGTCACTTGATGGAAAAAAGC-3 
and 5-ATTTGGTTGAACTTTTCCAG-3 for hEDEM3. These probes were 
labeled with digoxigenin. Subsequent reaction with anti-digoxigenin anti-
body (Roche) and treatment with the chemiluminescent detection reagent 
CDP-star (GE Healthcare) were performed according to the manufacturer’s 
specifications. Chemiluminescence was visualized using an LAS-3000mini 
LuminoImage analyzer.
Genomic PCR
Homologous recombination in HCT116 cells was confirmed by genomic 
PCR using a pair of primers: 5-CTATGTGCCAGCTACCATGTG-3 and 
5-TACTCCATGGAGGCCAAGCC-3 for hEDEM1, 5-CCCCAGGGTAGT-
CATTTGTC-3 and 5-ATCTGGCGCGGAGCCGTCGG-3 for hEDEM2, or 
5-GAGTACAGAGAGAAAAAGGAC-3 and 5-GCCACTAGTCTCCATC-
GCGC-3 for hEDEM3. The presence of the ampicillin-resistance gene in 
targeted alleles was checked by genomic PCR using a pair of primers: 
5-GAGCACTTTTAAAGTTCTGC-3 and 5-TTACCAATGCTTAATCAGTG-3.
RT-PCR
Total RNA prepared from WT DT40 cells or various KOs (5 × 106 cells) 
and from WT HCT116 cells or various KOs (3 × 106 cells) by the acid 
guanidinium/phenol/chloroform method using ISOGEN (Nippon Gene) 
was converted to cDNA using Moloney murine leukemia virus reverse tran-
scription (Invitrogen) and random primers. Full-length open reading frame 
of gEDEM1, gEDEM2, gEDEM3, gERmanI, hEDEM1, hEDEM2, or hEDEM3 
was amplified using PrimeSTAR HS DNA polymerase (Takara Bio Inc.) 
and a pair of primers, namely, 5-GGGTACCATGCAATGGCGCTCGCT-
GGT-3 and 5-CTCTAGAGATCAAGCCCACCATCCGAT-3 for gEDEM1, 
5-GGAATTCACCATGGCGCTGCTGCGCTCGCT-3 and 5-GCAGATCT-
GGAGTGTTGTCCAGGAAGACCT-3 for gEDEM2, 5-GGAATTCACCAT-
GGGCGGAGCTGCGGGCTG-3 and 5-CTATCGATGGTAGTTCATCCTT-
TTCCATCA-3 for gEDEM3, 5-GAAGATCTCGCCATGTACGCTGCCGC-
CGCC-3 and 5-GCTCTAGATGCTGGCACCCAGATGGGGAG-3 for 
gERmanI, 5-GAAGATCTGACCATGCAATGGCGAGCGCTC-3 and 
5-CGGGATCCAATCAAACCAACCATCTGGTC-3 for hEDEM1, 5-CCC-
AAGCTTGCTCTATGCCTTTCCGGCTGC-3 and 5-GCTCTAGATGAG-




In vitro translation was performed using the TNT Quick Coupled Transcrip-
tion/Translation Systems (Promega) and EASY TAG EXPRESS Protein label-
ing mix [35S] (PerkinElmer) according to the manufacturer’s instructions. 
Translated proteins were subjected to SDS-PAGE (12% gel) and radiolabeled 
proteins were visualized using an FLA-3000G FluoroImage analyzer.
Construction of gEDEM1 targeting vector
The 3.6-kb fragment of the gEDEM1 gene used for the 5 arm was amplified 
by PCR from DT40 cell genomic DNA using the primers 5-CCTCGAGTG-
GAGCTGTACCTGCTGTTG-3 and 5-CGGATCCGTAGCTGTCGTAGCC-
GAAGG-3, and then subcloned between the XhoI and BamHI sites of 
pBluescript II KS (+) vector to create the pBluescript-5 arm (gEDEM1). The 
2.3-kb fragment of the gEDEM1 gene used for the 3 arm was amplified sim-
ilarly using the primers 5-CCGGATCCGGGAAATTCTTCCGAGTTCC-3  
and 5-CCCTCGAGGGAACTCCCTTCTTCAGGTTG-3, and then subcloned 
between the BamHI and NotI sites of the pBluescript-5 arm (gEDEM1) 
to create the pBluescript-5-3 arms (gEDEM1). The puromycin-resistance 
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of the hEDEM3 gene used for the 3 arm was amplified similarly using the 
primers 5-ATAAGAATGCGGCCGCAGCGCGATGGAGACTAGTGG-3  
and 5-ATAAGAATGCGGCCGCTTTGCAATGATTTAAAGTAC-3, and then 
subcloned into the NotI site of the DT-A-pA/loxP/PGK-Zeo-pA/loxP-5 arm 
(hEDEM3) to create pKO-hEDEM3-Zeocin, which was transfected into 
HCT116 cells. Approximately 20 colonies were obtained 23 d later.
Online supplemental material
Fig. S1 shows how DT40 cells deficient in gEDEM1, gEDEM2, gEDEM3, 
or gERmanI are generated by homologous recombination. Fig. S2 shows 
characterization of high-mannose-type oligosaccharides of total glyco-
proteins prepared from DT40 cells of various genotypes. Fig. S3 shows 
characterization of HCT116 cells deficient in hEDEM1, hEDEM2, or hEDEM3 
including Southern blot hybridization for confirmation of correct target-
ing and characterization of high-mannose-type oligosaccharides of total 
glycoproteins prepared from HCT116 cells of various genotypes. Online 
supplemental material is available at http://www.jcb.org/cgi/content/ 
full/jcb.201404075/DC1.
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// (loxP) #1 and #2 using a pair of primers (5-CGCAAGCTTGC-
GGCCATGGCGCTGCTGCG-3 and 5-CGCTCTAGATCAAGTGTTGTC-
CAGGAAGAC-3), and then subcloned between the HindIII and XbaI sites 
of pcDNA3.1(+) (Invitrogen). Sequencing of the resulting plasmids re-
vealed that gEDEM2 cDNA obtained from gEDEM2 // (loxP) #1 
and #2 was a mixture of two cDNAs designated a and b and that both 
contained one or two deletions, which created a stop codon in exon 5 
(Fig. S1 K). Indeed, in vitro translation of the fragment did not produce any 
protein, whereas that of the WT fragment produced a protein of 75 kD, as 
expected (Fig. S1 K). We thus used // (loxP) #1 as gEDEM2-KO 
(Fig. 2 A). Two independent clones (/ #1 and #2) in which both alleles 
of the gEDEM3 gene were disrupted by EcoGPT and HisD or Neo-loxP 
were obtained (Fig. S1, H and I). As RT-PCR analysis showed that gEDEM3 
mRNA was not expressed in these clones (Fig. S1 J), we used / #1 as 
gEDEM3-KO (Fig. 2 A).
Exons encoding the transmembrane domain of gERmanI were re-
placed with drug-resistance genes (Fig. S1 L). Two independent clones (/ 
#1 and #2) in which both alleles of the gERmanI gene were disrupted by 
Neo-loxP and Puro-loxP were obtained (Fig. S1, M and N). As RT-PCR 
analysis showed that gERmanI mRNA was not expressed in these clones 
(Fig. S1 O), we used / #1 as gERmanI-KO (Fig. 2 A).
Construction of human targeting vectors
The DT-A-pA/loxP/PGK-Neo-pA/loxP vector was provided by Laboratory 
for Animal Resources and Genetic Engineering, Center for Developmental 
Biology, Institute of Physical and Chemical Research, Kobe, Japan. The 
puromycin- and zeocin-resistance genes were amplified from pPur (Takara 
Bio Inc.) and pVgRXR (Invitrogen) vectors, respectively, by PCR using the 
primers 5-CGACCTGCAGCCAATATGACCGAGTACAAGCCCACGG-3 
and 5-TTACAGCGGATCCCCTCAGGCACCGGGCTTGC-3 and 5-CG-
ACCTGCAGCCAATATGGCCAAGTTGACCAGTGCC-3 and 5-TTACAG-
CGGATCCCCTCAGTCCTGCTCCTCGGCC-3, respectively, and then inserted 
using the In-Fusion cloning method (Takara Bio Inc.) into the inverse PCR 
product of DT-A-pA/loxP/PGK-Neo-pA/loxP amplified with the primers 
5-GGGGATCCGCTGTAAGTCTGC-3 and 5-ATTGGCTGCAGGTCGAAA-
GGC-3, resulting in obtaining DT-A-pA/loxP/PGK-Puro-pA/loxP and DT-A-pA/
loxP/PGK-Zeo-pA/loxP, respectively, in which the neomycin-resistance gene 
was replaced with the puromycin- and zeocin-resistance genes, respectively.
Construction of hEDEM1 targeting vector
The 1.5-kb fragment of the hEDEM1 gene used for the 5 arm was am-
plified by PCR from HCT116 cell genomic DNA using the primers 
5-ATAAGAATGCGGCCGCGTGCTCCTCCGGCTTGGCCTC-3 and 5-CCC-
AAGCTTCCTTATCAGAACCTAAG-3, and then subcloned between the 
NotI and HindIII sites of the DT-A-pA/loxP/PGK-Neo-pA/loxP vector to 
create the DT-A-pA/loxP/PGK-Neo-pA/loxP-5 arm (hEDEM1). The 1.5-kb 
fragment of the hEDEM1 gene used for the 3 arm was amplified similarly 
using the primers 5-GGGGTACCAAGTGTTTTCTTAGTTCCC-3 and 5-CCG-
CTCGAGCAGCCCCAGGACGAGCGCTC-3, and then subcloned be-
tween the KpnI and XhoI sites of the DT-A-pA/loxP/PGK-Neo-pA/loxP-5 
arm (hEDEM1) to create pKO-hEDEM1-Neo, which was transfected into 
HCT116 cells. Approximately 100 colonies were obtained 20 d later.
Construction of hEDEM2 targeting vector
The 1.5-kb fragment of the hEDEM2 gene used for the 5 arm was am-
plified by PCR from HCT116 cell genomic DNA using the primers 
5-GGGGTACCGCGCGATCCTCGCTCACTGC-3 and 5-CCGCTCGAG-
CCGGAAAGGCATAGAGCTCG-3, and then subcloned between the KpnI 
and XhoI sites of the DT-A-pA/loxP/PGK-Puro-pA/loxP vector to create the 
DT-A-pA/loxP/PGK-Puro-pA/loxP-5 arm (hEDEM2). The 1.5-kb fragment 
of the hEDEM2 gene used for the 3 arm was amplified similarly using the 
primers 5-ATAAGAATGCGGCCGCTGTGCGCGCTGCTGCCTCAG-3 
and 5-CCCAAGCTTGGTCACTTCAAACGAGTGTAG-3, and then sub-
cloned between the NotI and HindIII sites of the DT-A-pA/loxP/PGK-Puro-
pA/loxP-5 arm (hEDEM2) to create pKO-hEDEM2-Puromycin, which was 
transfected into HCT116 cells. Approximately 100 colonies were obtained 
17 d later.
Construction of hEDEM3 targeting vector
The 1.5-kb fragment of the hEDEM3 gene used for the 5 arm was am-
plified by PCR from HCT116 cell genomic DNA using the primers 
5-GGGGTACCGAAAACCTTAAGGGAACACC-3 and 5-CCGCTCGAGC-
GCTGGGGAACCGGGGACCC3, and then subcloned between the KpnI 
and XhoI sites of the DT-A-pA/loxP/PGK-Zeo-pA/loxP vector to create the 
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